

**From:** Maruna, Thomas  
**Sent:** Wednesday, September 10, 2014 1:00 PM  
**To:** Allison Kennedy (akennedy@ebsi.com); 'smcgregor@ebsi.com'  
**Cc:** Wernly, Claire; Fisher, Robert  
**Subject:** Information Requested: BLA 125562/0 - Please Respond by September 26, 2014

**Importance:** High

Cangene Corporation [Emergent Biosolutions]  
Attention: Ms. Allison Kennedy  
September 10, 2014  
Sent by email

Dear Ms. Kennedy:

We are reviewing your July 25, 2014 biologics license application (BLA) indicated for the treatment of adult and pediatric patients with toxemia associated with inhalational anthrax for the following:

<b>STN</b>	<b>Name of Biological Products</b>
BL 125562	Anthrax Immune Globulin Intravenous (Human)

We determined that the following information is necessary to continue our review:

1. Please provide the bioburden qualification report for AIGIV, showing the suitability of the test method used, conformance and recovery of inoculated microorganisms in the presence and absence of drug product (to include lot numbers), and relevant negative controls in accordance with (b) (4) and (b) (4)
2. Please provide the sterility qualification report for AIGIV showing the test was qualified in accordance with (b) (4) to confirm the product matrix for the final container drug product is suitable for the intended test method. Please include the indicator microorganisms tested, their media, conformance lot numbers, and incubation conditions used in the qualification.
3. Please provide the (b) (4) endotoxin test qualification report for AIGIV showing the drug product matrix is suitable for the intended test method (in accordance with (b) (4) to include maximal valid dilution, tested dilutions, positive product control percent recoveries, lot numbers, selected testing dilution and endotoxin test results.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your responses as an amendment to this file by September 26, 2014 referencing the date of this request.

If Cangene is unable to respond by September 26<sup>th</sup>, please propose an alternative date to respond.

The action due date for these files is March 25, 2014.

If you have any questions, please contact me.

Very Respectfully,

Thomas J. Maruna, MSc, MLS(ASCP)<sup>CM</sup>

Lieutenant, U.S. Public Health Service

Senior Regulatory Management Officer

Food and Drug Administration

Center for Biologics Evaluation and Research

Office of Blood Research and Review

10903 New Hampshire Ave.

Silver Spring, MD 20993

[thomas.maruna@fda.hhs.gov](mailto:thomas.maruna@fda.hhs.gov)

O: (240) 402-8454

[www.usphs.gov](http://www.usphs.gov)



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."